JP2025508075A - 抗ｉｌｔ２抗体及びその使用 - Google Patents

抗ｉｌｔ２抗体及びその使用 Download PDF

Info

Publication number
JP2025508075A
JP2025508075A JP2024553452A JP2024553452A JP2025508075A JP 2025508075 A JP2025508075 A JP 2025508075A JP 2024553452 A JP2024553452 A JP 2024553452A JP 2024553452 A JP2024553452 A JP 2024553452A JP 2025508075 A JP2025508075 A JP 2025508075A
Authority
JP
Japan
Prior art keywords
antibody
ilt2
amino acid
antibodies
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024553452A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025508075A5 (https=
Inventor
ブラヌサ，ミラン
シュルツ，コーネリア
シュースター，アンドレア，クラウディア
ブレンド，エマニュアル，シリル，パスカル
イグナトヴィッチ，オルガ
サヴィツキー，デビッド，アダム
ブッシェル，ケー．，マーク
ウェンズレー，ベス
ガランド，クレア
プペッカ－スワイダー，マウゴジャータ
Original Assignee
アジェナス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アジェナス インコーポレイテッド filed Critical アジェナス インコーポレイテッド
Publication of JP2025508075A publication Critical patent/JP2025508075A/ja
Publication of JP2025508075A5 publication Critical patent/JP2025508075A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2024553452A 2022-03-07 2023-03-07 抗ｉｌｔ２抗体及びその使用 Pending JP2025508075A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263268945P 2022-03-07 2022-03-07
US63/268,945 2022-03-07
PCT/US2023/063821 WO2023172890A2 (en) 2022-03-07 2023-03-07 Anti-ilt2 antibodies and uses thereof

Publications (2)

Publication Number Publication Date
JP2025508075A true JP2025508075A (ja) 2025-03-21
JP2025508075A5 JP2025508075A5 (https=) 2026-03-12

Family

ID=87935886

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024553452A Pending JP2025508075A (ja) 2022-03-07 2023-03-07 抗ｉｌｔ２抗体及びその使用

Country Status (10)

Country Link
US (1) US20250109201A1 (https=)
EP (1) EP4490196A2 (https=)
JP (1) JP2025508075A (https=)
KR (1) KR20250004950A (https=)
CN (1) CN119365487A (https=)
AU (1) AU2023231622A1 (https=)
CA (1) CA3254318A1 (https=)
IL (1) IL315487A (https=)
MX (1) MX2024010982A (https=)
WO (1) WO2023172890A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025059304A2 (en) * 2023-09-12 2025-03-20 Agenus Inc. Methods of treating cancer using ilt2 antibodies and combination therapies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
EP1678195A4 (en) * 2003-10-08 2008-04-23 The Feinstein Inst Medical Res METHOD AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF CHRONIC LYMPHOCYTIC B-CELL LEUKEMIA
WO2018148494A1 (en) * 2017-02-09 2018-08-16 Bluefin Biomedicine, Inc. Anti-ilt3 antibodies and antibody drug conjugates
MX2021015024A (es) * 2020-04-28 2022-01-18 Univ Rockefeller Anticuerpos anti-sars-cov-2 ampliamente neutralizantes y métodos de uso de los mismos.
MY209480A (en) * 2020-05-01 2025-07-11 Ngm Biopharmaceuticals Inc Ilt-binding agents and methods of use thereof

Also Published As

Publication number Publication date
AU2023231622A1 (en) 2024-09-26
WO2023172890A2 (en) 2023-09-14
CA3254318A1 (en) 2023-09-14
EP4490196A2 (en) 2025-01-15
CN119365487A (zh) 2025-01-24
WO2023172890A3 (en) 2023-10-19
IL315487A (en) 2024-11-01
US20250109201A1 (en) 2025-04-03
MX2024010982A (es) 2025-02-10
KR20250004950A (ko) 2025-01-09

Similar Documents

Publication Publication Date Title
JP2020500538A (ja) 抗ｃｔｌａ−４抗体およびそれらの使用方法
IL302808B1 (en) Anti-LAG-3 antibodies and methods of using them
CN110546166A (zh) 抗cd137抗体和其使用方法
KR20230028478A (ko) 항-ctla-4 항체 및 이의 사용 방법
US11680098B2 (en) Antibodies that specifically bind human CD96
US20220389095A1 (en) Anti-tigit antibodies and methods of use thereof
US20250109201A1 (en) Anti-ilt2 antibodies and uses thereof
JP2024516843A (ja) 抗ｔｉｇｉｔ抗体、抗ｃｄ９６抗体、及びそれらの使用の方法
US20250250361A1 (en) Anti-pla2g10 antibodies and methods of use
WO2024263882A2 (en) Anti-klrg1 antibodies and uses thereof
WO2024073474A2 (en) Anti-pla2g10 antibodies and methods of use
TW202321296A (zh) 抗間皮素抗原結合分子及其用途
WO2025049908A1 (en) Anti-pla2g10 antibodies and methods of use
WO2025076445A1 (en) Anti-fap antibodies and methods of use thereof
HK40076263A (en) Anti-cd96 antibodies and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260304

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260304